2024
Win Ratio Analyses Using a Modified Hierarchical Composite Outcome: Insights From PARAGLIDE-HF
Shoji S, Cyr D, Hernandez A, Velazquez E, Ward J, Williamson K, Sarwat S, Starling R, Desai A, Zieroth S, Solomon S, Mentz R. Win Ratio Analyses Using a Modified Hierarchical Composite Outcome: Insights From PARAGLIDE-HF. American Heart Journal 2024, 280: 70-78. PMID: 39505123, DOI: 10.1016/j.ahj.2024.10.020.Peer-Reviewed Original ResearchNT-proBNPComposite outcomeRenal outcomesEjection fractionHeart failureN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideNT-proBNP thresholdsNT-proBNP changesClinically significant eventsNatriuretic peptideAssessment of treatment effectsHF hospitalizationCardiovascular deathTreatment effectsTreatment benefitComprehensive assessment of treatment effectsPrimary analysisValsartanHF visitsSecondary analysisPatientsHierarchical outcomesOutcomes
2023
Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure
Mentz R, Anstrom K, Eisenstein E, Sapp S, Greene S, Morgan S, Testani J, Harrington A, Sachdev V, Ketema F, Kim D, Desvigne-Nickens P, Pitt B, Velazquez E, Adams K, Bhatt K, DeWald T, Axsom K, Murthy S, Rich J, Testani J, Smith B, Vader J, McCulloch M, Skopicki H, Psotka M, Heroux A, Lala-Trindade A, Stevens G, Tang W, Lev Y, William P, Eberly A, Gottleib S, Haught W, Grafton G, Larned J, Tejwani L, Mody F, Krim S, Robinson M, Fang J, Adler A, Bell A, Banerjee D, Ruiz Duque E, Mizyed A, Rommel J, Arhinful J, Goyal P, Hall M, Hummel S, Shetty S, Haas D, Vilaro J, Alexy T, Herre J, Clark J, Ambrosy A, Gaglianello N, Ramasubbu K, Meadows J, Tabtabai S, Sherwood M, Hasni S, D'Urso M, Muneer B, Dunlap S, Davis W, Friedman D, Guglin M, Ferguson A, Abbate A, Smart F. Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure. JAMA 2023, 329: 214-223. PMID: 36648467, PMCID: PMC9857435, DOI: 10.1001/jama.2022.23924.Peer-Reviewed Original ResearchConceptsCause mortalityHeart failureTorsemide groupFurosemide groupTotal hospitalizationsCause hospitalizationEffects of torsemideDiuretic strategyPrespecified subgroupsSecondary outcomesEjection fractionMedian agePrimary outcomeHospitalizationMAIN OUTCOMEPatientsFurosemideMortalityMonthsTorsemidePrimary hypothesisSignificant differencesFinal dateOutcomesTrials
2019
Association between systolic ejection time and outcomes in heart failure by ejection fraction
Patel PA, Ambrosy AP, Phelan M, Alenezi F, Chiswell K, Van Dyke MK, Tomfohr J, Honarpour N, Velazquez EJ. Association between systolic ejection time and outcomes in heart failure by ejection fraction. European Journal Of Heart Failure 2019, 22: 1174-1182. PMID: 31863532, PMCID: PMC7493053, DOI: 10.1002/ejhf.1659.Peer-Reviewed Original ResearchConceptsSystolic ejection timeEjection fractionHeart failureClinical outcomesVentricular systolic ejection timeOutpatient transthoracic echocardiogramReduced ejection fractionTertiary referral centerMultivariable logistic regressionHFrEF patientsHF patientsReferral centerTransthoracic echocardiogramAmbulatory patientsHF populationEjection timeEligibility criteriaLogistic regressionPatientsOutcomesAssociationHFpEFEchocardiogram
2015
Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial
Mentz RJ, Velazquez EJ, Metra M, McKendry C, Chiswell K, Fiuzat M, Givertz MM, Voors AA, Teerlink JR, O'Connor CM. Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial. Future Cardiology 2015, 11: 585-595. PMID: 26403536, PMCID: PMC5558519, DOI: 10.2217/fca.15.56.Peer-Reviewed Original ResearchConceptsPROTECT trialComparative effectivenessHigher blood urea nitrogenEffects of torsemideProspective randomized trialsHeart failure patientsBlood urea nitrogenGreater disease severityDays postdischargeFailure patientsHeart failureLoop diureticsRandomized trialsRenal hospitalizationUrea nitrogenDisease severityPatientsFurosemideInverse probabilityTorsemideTrialsDeathOutcomesHospitalizationDiuretics
2008
High-risk myocardial infarction in the young: The VALsartan In Acute myocardial iNfarcTion (VALIANT) trial
Anderson RE, Pfeffer MA, Thune JJ, McMurray JJ, Califf RM, Velazquez E, White HD, Rouleau JL, Skali H, Maggioni A, Solomon SD. High-risk myocardial infarction in the young: The VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. American Heart Journal 2008, 155: 706-711. PMID: 18371480, DOI: 10.1016/j.ahj.2007.11.016.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsCardiovascular DiseasesDiabetes ComplicationsFemaleHumansHypertensionKaplan-Meier EstimateMaleMiddle AgedMortalityMultivariate AnalysisMyocardial InfarctionProportional Hazards ModelsRisk FactorsSex FactorsSmokingSurvivorsTetrazolesValineValsartanConceptsAcute myocardial infarctionAcute Myocardial Infarction trialMyocardial Infarction trialRisk factorsMyocardial infarctionHigh-risk myocardial infarctionCardiovascular event ratesInfluence of hypertensionMultivariate Cox regressionPrognostic risk factorsHistory of MICardiovascular outcomesCurrent smokersLess diabetesYounger patientsCox regressionPost-AMIAdvanced ageRelative riskYoung survivorsAge groupsHypertensionEvent ratesPatientsOutcomes
2004
Newly Diagnosed and Previously Known Diabetes Mellitus and 1-Year Outcomes of Acute Myocardial Infarction
Aguilar D, Solomon SD, Køber L, Rouleau JL, Skali H, McMurray JJ, Francis GS, Henis M, O’Connor C, Diaz R, Belenkov YN, Varshavsky S, Leimberger JD, Velazquez EJ, Califf RM, Pfeffer MA. Newly Diagnosed and Previously Known Diabetes Mellitus and 1-Year Outcomes of Acute Myocardial Infarction. Circulation 2004, 110: 1572-1578. PMID: 15364810, DOI: 10.1161/01.cir.0000142047.28024.f2.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsCaptoprilCohort StudiesComorbidityDiabetes ComplicationsDiabetes MellitusDrug Therapy, CombinationFemaleFollow-Up StudiesHeart FailureHumansLife TablesMaleMedical RecordsMiddle AgedMulticenter Studies as TopicMyocardial InfarctionProportional Hazards ModelsRandomized Controlled Trials as TopicRiskStrokeTetrazolesTime FactorsTreatment OutcomeValineValsartanVentricular Dysfunction, LeftConceptsAcute myocardial infarctionMyocardial infarctionCardiovascular eventsDiabetes mellitusAdverse outcomesAcute Myocardial Infarction trialPoor long-term outcomesMajor cardiovascular eventsMyocardial Infarction trialHigh-risk patientsRisk of deathLong-term outcomesRisk of mortalityBaseline characteristicsDiabetic statusComorbid conditionsMetabolic abnormalitiesPrior diagnosisPoor prognosisNew diagnosisDiabetesPatientsMellitusOutcomesInfarction